CNTX

TentativeAI Memo

Context Therapeutics

As of 2026-10-18/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-18 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report

Action

—

Confidence

medium

Horizon

—

Key catalyst

CTIM-76 Phase 1b dose expansion • 2027-03-31

Base target: $0 / p=50% prob

Biggest risk

The encouraging weekly-dosing signal rests on only 2 responses among 7 evaluable ovarian-cancer patients at active doses, and may not carry over to every-three-week dosing or expansion Context trial update. Context discontinued CT-95 to prioritize CTIM-76 and CT-202, increasing dependence on those programs [#PR-EARNINGS-2026-08-05].

Invalidation

Break below $0 or thesis failure.

What would change my mind?

Successful CTIM-76 dosing and a larger, reproducible ovarian-cancer response dataset could re-rate the shares; CT-202 adds a separate clinical option. Context reported $43.0 million of June 30 cash and expected it to fund operations into Q4 2027 [#PR-EARNINGS-2026-08-05].

Research note

Recommendation

—

Confidence

medium

As of

2026-10-18

Base target

p=50%

Bull target

p=20%

Bear target

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

CTIM-76 every-three-week dosing
CTIM-76 every-three-week clinical readout
CT-202 initial clinical data

BearKey bullets

CT-95 discontinuation narrows the active pipeline; CT-202 has no reported patient efficacy result [#PR-EARNINGS-2026-08-05].
Cash declined from $66.0 million at December 31, 2025 to $43.0 million at June 30, 2026; the stated Q4 2027 runway is a company projection, not financing assurance [#PR-EARNINGS-2026-08-05].
Every-three-week dosing could reveal different efficacy or safety, and enrollment or Phase 1b timing could slip [#PR-EARNINGS-2026-08-05].

WatchKey bullets

CTIM-76 Phase 1b dose expansion

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $0 (p=50%)

Target spread vs base: +120% / -64%

Scenario probabilities

Bull Target: $1 (p=20%)Base Target: $0 (p=50%)Bear Target: $0 (p=30%)

Commentary

The October 16 packet anchor of $0.244 is about 20% below the prior baseline's October 9 anchor of $0.3042. September CT-202 first-patient dosing resolved an execution milestone but supplied no efficacy evidence Context announcement. The August 8-K furnished a corporate presentation, not a newer clinical result [#8-K-2026-08-05]. Recent analyst revisions, a verified event-linked price reaction, options skew, short interest, employee scores and sufficient social coverage are unavailable; zero sentiment fields mean unavailable, not neutral.

As of 2026-10-18 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

CTIM-76 every-three-week dosing
CTIM-76 every-three-week clinical readout
CT-202 initial clinical data

Scenarios

Bull Target (Scenario probability)

$1 / p=20% prob

Base Target (Scenario probability)

$0 / p=50% prob

Bear Target (Scenario probability)

$0 / p=30% prob

Analysis 2026-10-18 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2027-03-31
CTIM-76 Phase 1b dose expansion
The company targets Phase 1b dose-expansion initiation in Q1 2027, conditional on execution and the emerging dosing profile [#PR-EARNINGS-2026-08-05].
Prob 60.00% • Move 15.00% • Priced-in 35.00%

Short-term Catalysts

Next few weeks

CTIM-76 every-three-week dosing
2026-12-31
Context planned to evaluate CTIM-76 on an every-three-week schedule in less heavily pretreated platinum-resistant ovarian-cancer patients during the second half of 2026. Confirmation of enrollment and tolerability matters more than the schedule change alone [#PR-EARNINGS-2026-08-05].
Prob 65% • Move 10% • Priced-in 40%

Long-term Catalysts

Months to a year

CTIM-76 every-three-week clinical readout
2027-06-30
Initial Phase 1a safety, tolerability and efficacy data are expected in Q2 2027 [#PR-EARNINGS-2026-08-05]. The June weekly-dosing response rate was 2 of 7 evaluable ovarian-cancer patients at active doses, too small a group to predict the new-schedule result Context trial update.
Prob 55% • Move 50% • Priced-in 30%
CT-202 initial clinical data
2027-12-31
Context expects initial Phase 1a topline safety, tolerability and early efficacy data in the second half of 2027 [#PR-EARNINGS-2026-08-05]. First-patient dosing announced September 9, 2026 establishes trial initiation, not efficacy Context announcement.
Prob 50% • Move 35% • Priced-in 25%

Risks

CT-95 discontinuation narrows the active pipeline; CT-202 has no reported patient efficacy result [#PR-EARNINGS-2026-08-05].
Cash declined from $66.0 million at December 31, 2025 to $43.0 million at June 30, 2026; the stated Q4 2027 runway is a company projection, not financing assurance [#PR-EARNINGS-2026-08-05].
Every-three-week dosing could reveal different efficacy or safety, and enrollment or Phase 1b timing could slip [#PR-EARNINGS-2026-08-05].
Small, interim CTIM-76 dataset; response durability and reproducibility remain uncertain.

Peers

Symbol	Summary
XNCR	Xencor's clinical-stage CLDN6 x CD3 program offers a CTIM-76 mechanism comparison, but its broader pipeline makes its equity valuation a poor direct benchmark.
ONC	BeOne Medicines' Phase 1 CLDN6 x CD3 program offers a mechanism-and-stage comparison; its much broader business limits valuation comparability.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-18

Loading AI feed…

Symbol

Summary

XNCR

Xencor's clinical-stage CLDN6 x CD3 program offers a CTIM-76 mechanism comparison, but its broader pipeline makes its equity valuation a poor direct benchmark.

ONC

BeOne Medicines' Phase 1 CLDN6 x CD3 program offers a mechanism-and-stage comparison; its much broader business limits valuation comparability.